Tesamorelin + IpamorelinvsVK2735

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.

VK2735 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist with a structure optimised for high potency and a clean tolerability profile. Dual incretin receptor activation produces complementary effects on appetite, glucose handling, and energy expenditure: GLP-1 receptor agonism delivers central appetite suppression through hypothalamic arcuate-nucleus signalling, slows gastric emptying, and triggers glucose-dependent insulin secretion, while GIP receptor activation amplifies the insulin response, supports beta-cell function, and modulates adipose tissue lipid handling.

The molecule's pharmacokinetic profile delivers sustained receptor exposure across a one-week dosing interval, achieved through structural modifications that enable albumin binding and resistance to proteolytic degradation. In the Phase 2 VENTURE trial, the 15 mg dose produced 14.7% mean body weight loss at 13 weeks — the fastest early weight loss observed for any obesity drug, with the loss curve still descending steeply at trial end. This rapid trajectory suggests substantially greater total weight loss would be achievable with longer dosing, and Phase 3 VANQUISH trials launched in 2026 are testing 68-week treatment durations to characterise the full magnitude of effect.

Viking is also developing an oral tablet formulation of VK2735 in parallel, which entered Phase 1 in 2024-2025. If both formulations succeed, Viking would have one of the most flexible GLP-1/GIP product profiles on the market — though as a small biotech company it faces significant manufacturing and commercial scaling challenges relative to Lilly and Novo Nordisk.